| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
|
Xu, Jing
|
|
|
89 |
5 |
p. 683-695
|
article
|
| 2 |
Anti-drug antibodies in the current management of cancer
|
Borregón, Miguel
|
|
|
89 |
5 |
p. 577-584
|
article
|
| 3 |
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
|
Manzo, Julia
|
|
|
89 |
5 |
p. 721-735
|
article
|
| 4 |
Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
|
Jing, Jing
|
|
|
89 |
5 |
p. 707-720
|
article
|
| 5 |
ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy
|
Zhao, Lin
|
|
|
89 |
5 |
p. 595-607
|
article
|
| 6 |
Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study
|
T’jollyn, Huybrecht
|
|
|
89 |
5 |
p. 629-641
|
article
|
| 7 |
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
|
Fernández-Teruel, Carlos
|
|
|
89 |
5 |
p. 585-594
|
article
|
| 8 |
Is age just a number? A population pharmacokinetic study of gemcitabine
|
Boosman, René J.
|
|
|
89 |
5 |
p. 697-705
|
article
|
| 9 |
Lurbinectedin-induced thrombocytopenia: the role of body surface area
|
Papachristos, Apostolos
|
|
|
89 |
5 |
p. 573-575
|
article
|
| 10 |
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
|
Robinson, Reeder M.
|
|
|
89 |
5 |
p. 643-653
|
article
|
| 11 |
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
|
Büsker, Sören
|
|
|
89 |
5 |
p. 617-627
|
article
|
| 12 |
Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study
|
Xiong, Wenyuan
|
|
|
89 |
5 |
p. 655-669
|
article
|
| 13 |
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors
|
Green, Michelle L.
|
|
|
89 |
5 |
p. 671-682
|
article
|
| 14 |
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy
|
Fukuda, Natsuki
|
|
|
89 |
5 |
p. 609-616
|
article
|
Journal description